Regression of Human Mammary Adenocarcinoma by Systemic Administration of a Recombinant Gene Encoding the hFlex-TRAIL Fusion Protein
Open Access
- 1 March 2001
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 3 (3), 368-374
- https://doi.org/10.1006/mthe.2001.0280
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cellsEuropean Journal of Immunology, 1998
- An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAILScience, 1997
- FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in MiceCellular Immunology, 1997
- Interleukin 1β-converting Enzyme Related Proteases/Caspases Are Involved in TRAIL-induced Apoptosis of Myeloma and Leukemia CellsThe Journal of cell biology, 1997
- Apoptosis by Death FactorCell, 1997
- Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine FamilyJournal of Biological Chemistry, 1996
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995
- Structural characteristics of CD40 ligand that determine biological functionSeminars in Immunology, 1994
- Two TNF receptorsImmunology Today, 1992